The Largest Segment Driving The Growth Of Orthobiologics Market

Orthobiologics Market 


The global Orthobiologics Market is estimated to be valued at US$ 6899.6 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:


Orthobiologics are medical devices, tissues, and grafts used in orthopedic soft tissue surgeries and skeletal reconstructions. They enhance the healing process by facilitating bone growth and preventing complications. Bone substitute materials are used in orthopedic surgeries to replace damaged bones and improve healing.


Market key trends:


One of the key trends in the orthobiologics market is the rising demand for advanced bone graft substitutes and bone substitute materials. Advanced bone substitutes offer improved osteoconductivity and osteoinductivity compared to traditional autograft and allograft materials. They help stimulate new bone formation at the surgical site and can be easily molded to fill bone voids of complex anatomies. Demand for advanced synthetic and biologically-derived bone graft substitutes is increasing globally due to their ability to overcome limitations of traditional bone graft materials such as donor site pain, disease transmission and limited availability.


SWOT Analysis


Strength: Wide range of product offerings for bone healing and tissue regeneration. Weakness: High costs associated with R&D and production of orthobiologics. Opportunity: Untapped growth potential in developing regions. Threats: Stringent regulatory framework and reimbursement issues pose challenges.


Key Takeaways


The Global Orthobiologics Market Size was valued at US$ 6899.6 Mn in 2023 and is expected to exceed US$ 11600 Mn by 2030, expanding at a CAGR of 5.9% during the forecast period. The growing geriatric population suffering from orthopedic diseases and rising number of sports injuries are driving the market.
Regional analysis: North America dominated the orthobiologics market in 2023 with over 35% market share. However, Asia Pacific exhibits high growth potential due to rising healthcare expenditure and increasing focus on tissue engineering and regenerative medicine in countries like China and India.
Key players: Key players operating in the orthobiologics market are Zimmer Biomet, Bone Biologics Corp., Globus Medical, Smith & Nephew Inc., Stryker, ATEC Spine, Inc., XTANT MEDICAL, Johnson & Johnson Services, Inc., Exactech, Inc., Integra LifeSciences, Medtronic, NuVasive, Inc., Orthofix US LLC., SeaSpine, ChitogenX Inc., Spine Wave, Inc., Molecular Matrix, Inc., Isto Biologics, Baxter, Locate Bio Limited, Cerapedics, Ossifix Orthopedics, and Aziyo.


Read More - https://www.insightprobing.com/orthobiologics-market-size-and-share-trends-analysis-growth-and-forecasts/

 

Comments

Post a Comment

Popular posts from this blog

Riding the Wave: Navigating Dynamics in the Windsurf Foil Board Market

Image
   Windsurf Foil Board Market In the exhilarating world of water sports, the Windsurf Foil Board Market emerges as a key player, offering enthusiasts innovative equipment to enhance their riding experience. As this niche market continues to gain traction among windsurfing aficionados worldwide, it undergoes significant shifts influenced by various drivers, challenges, and geographical nuances. The Windsurf Foil Board Market size was valued at  US$ 167.4 Mn in 2024  and is expected to reach  US$ 268.6 Mn by 2031 , growing at a compound annual growth rate  (CAGR) of 7% from 2024 to 2031 Key Takeaways A prominent trend in the Windsurf Foil Board Market Demand is the increasing adoption of foil technology. Foil boards, equipped with hydrofoils beneath the waterline, enable riders to glide effortlessly above the water's surface, providing a thrilling and dynamic experience. This technological innovation has revolutionized the windsurfing landscape, attrac...
Read more

Idiopathic Hypersomnia Treatment Market is Anticipated to Witness High Growth Owing to Increasing Prevalence of Idiopathic Hypersomnia

Image
  Idiopathic Hypersomnia Treatment Market Idiopathic hypersomnia is a neurological sleep disorder characterized by excessive daytime sleepiness and long periods of sleep that does not improve even after long sleep. The treatment of idiopathic hypersomnia is done through medication and behavioral therapies. Medications like psychostimulants, serotonin modulators, wakefulness promoting agents are used to treat the condition and increase wakefulness. The increasing prevalence of idiopathic hypersomnia due to genetic and environmental factors is expected to drive the growth of the idiopathic hypersomnia treatment market. The Global Idiopathic Hypersomnia Treatment Market is estimated to be valued at US$ 389.86 Mn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 to 2030. Key Takeaways Key players operating in the Idiopathic Hypersomnia Treatment Market are Esaote SPA, Epica Animal Health, IDEXX Laboratories, Carestream Health, IMV Imaging, Fujifilm Hold...
Read more

Navigating Opportunities In The Niemann-Pick Disease Drug Type C Treatment Market

Image
  Niemann-Pick Disease Drug Type C Treatment Market Key Takeaways The Niemann-Pick Disease Drug Type C Treatment Market is witnessing significant growth, driven by advancements in medical research and a deeper understanding of the disease pathology. Niemann-Pick Disease Type C (NPC) is a rare genetic disorder characterized by the accumulation of cholesterol and other lipids within cells, leading to progressive neurological and visceral symptoms. With an increasing focus on rare diseases and orphan drug development, the market for NPC treatment is expanding rapidly, offering hope to patients and caregivers. Key players in the pharmaceutical industry are actively investing in research and development to bring novel therapies to market, underscoring the potential for transformative interventions in NPC management. Global Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at  US$ 45.40  million  in 2024, and is expected to exhibit a  CAG...
Read more